Claims for Patent: 6,797,815

Summary for Patent: 6,797,815

Title:	Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
Abstract:	Novel xylo nucleoside or xylo nucleotide analogs, polynucleotides comprising xylo nucleotide substitution, processes for their synthesis and incorporation into polynucleotides.
Inventor(s):	Matulic-Adamic; Jasenka (Boulder, CO), Beigelman; Leonid (Longmont, CO)
Assignee:	Sirna Therapeutics, Inc. (Boulder, CO)
Application Number:	10/277,263
Patent Claims:	1. A compound having the formula I: ##STR5## wherein, R.sub.1 is OH, O--R.sub.3, wherein R.sub.3 is independently a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester, C--R.sub.3, wherein R.sub.3 is independently a moiety selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester, halo, NHR.sub.4, wherein R.sub.4 is independently a moiety selected from the group consisting of alkyl (C1-22), acyl (C1-22), substituted or unsubstituted aryl, or OCH.sub.2 SCH.sub.3 (methylthiomethyl), ONHR.sub.5, wherein R.sub.5 is independently a moiety selected from the group consisting of H, aminoacyl group, peptidyl group, biotinyl group, cholesteryl group, lipoic acid residue, retinoic acid residue, folic acid residue, ascorbic acid residue, nicotinic acid residue, 6-aminopenicillanic acid residue, 7-aminocephalosporanic acid residue, alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide or ester, ON=R.sub.6, wherein R.sub.6 is independently a moiety selected from the group consisting of pyridoxal residue, pyridoxal-5-phosphate residue, 13-cis-retinal residue, 9-cis-retinal residue, alkyl, alkenyl, alkynyl, alkylaryl, carbocyclic alkylaryl, or heterocyclic alkylaryl; B is independently a nucleotide base or hydrogen; X is independently a phosphorus-containing group; and R.sub.2 is independently a blocking group or a phosphorus-containing group. 2. The compound of claim 1, wherein said compound is a nucleotide. 3. The compound of claim 1, wherein said compound is a nucleotide-triphosphate. 4. A polynucleotide comprising the compound of claim 1 at one or more positions. 5. The polynucleotide of claim 4, wherein said polynucleotide is an enzymatic nucleic acid. 6. The enzymatic nucleic acid of claim 5, wherein said nucleic acid is in a hammerhead configuration. 7. The enzymatic nucleic acid of claim 6, wherein said nucleic acid is in a hairpin configuration. 8. The enzymatic nucleic acid of claim 6, wherein said nucleic acid is in a hepatitis delta virus, group I intron, VS RNA, group II intron or RNase P RNA configuration. 9. The compound of claim 1, wherein said compound is xylo riboadenosine. 10. The compound of claim 1, wherein said compound is xylo riboguanosine. 11. The compound of claim 1, wherein said compound is xylo ribonucleoside phosphoramidite. 12. The compound of claim 11, wherein said compound is xylo riboguanosine phosphoramidite. 13. The compound of claim 11, wherein said compound is xylo riboadenosine phosphoramidite. 14. A pharmaceutical composition comprising a compound of claim 1. 15. A pharmaceutical composition comprising a polynucleotide of claim 5. 16. The compound of claim 1, wherein said compound is used as an antiviral agent.

Details for Patent 6,797,815

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-08-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-08-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-08-22